Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Table 2 Evaluation of neoadjuvant therapy efficacy

Index	Evaluation	Erlotinib arm n = 12, (%)	GC arm n = 12, (%)	P value
RECIST	PR	7/12 (58.33)	3/12 (25.00)	0.18
	SD	2/12 (16.67)	6/12 (50.00)
	PD*	3/12 (25.00)	2/12 (16.67)
	NA	0 (0.00)	1/12 (8.33)
Clinical N2 downstaging		3/12 (25.00)	3/12 (25.00)	1.00
Pathological N2 downstaging		2/12 (16.67)	3/12 (25.00)	0.64
Resection	R0	3/6 (50.00)	5/7 (71.43)	0.59
	R1	3/6 (50.00)	2/7 (28.57)

Values are presented as n (percentage)
GC gemcitabine/carboplatin, RECIST Response Evaluation Criteria in Solid Tumors, PR partial response, SD stable disease, PD progressive disease, NA not available
*Two patients with the EGFR L858R mutation and the KRAS mutation or EML4-ALK translocation developed primary resistance to induction erlotinib

ISSN: 1756-8722